Nicox and Vester Finance Enter Strategic Shareholder Loan Agreement

Nicox SA announces a shareholder loan agreement with Vester Finance, offering up to €6.0 million over three years. The ophthalmology company, traded on Euronext Growth Paris, aims to enhance flexibility in its strategic activities. The arrangement, set under specific contractual conditions, includes an optional facility without requiring Nicox to draw any amount.

Repayment options include new shares or cash, with a maximum 16% potential dilution capped. The loan carries a 7% annual interest, applicable only for cash repayments. Nicox anticipates operating costs covered beyond 2027, supported by expected milestone payments and sales revenue from NCX 470.

Future milestones include NCX 470 New Drug Application submissions in the U.S. and China and the initiation of a Phase 3 clinical program in Japan. The agreement adheres to existing market rules, promising minimal impact on governance and shareholder equity.